Mutant Bik expression mediated by the enhanced minimal topoisomerase IIα promoter selectively suppressed breast tumors in an animal model

Cancer Gene Therapy

Volumn 13, Issue 7, 2006, Pages 706-719

  Day, C P ^a,b   Rau, K M ^a,d   Qiu, L ^a   Liu, C W ^a   Kuo, H P ^a   Xie, X ^a   Lopez Berestein, G ^a,b   Hortobagyi, G N ^a   Hung, M C ^a,b,c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

BikDD; Breast cancer; Liposome; Topoisomerase IIa promoter

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; CHOLESTEROL DERIVATIVE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IIALPHA; GENE PRODUCT; LIPOSOME; MUTANT PROTEIN; PROTEIN BIK; PROTEIN BIKDD; PROTEIN CT90; UNCLASSIFIED DRUG;

ALPHA CHAIN; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIKDD GENE; BREAST CANCER; BREAST TUMOR; CANCER INHIBITION; CANCER THERAPY; CARCINOGENESIS; CONTROLLED STUDY; CT90 GENE; CYTOMEGALOVIRUS; DNA SEQUENCE; DRUG DELIVERY SYSTEM; ENHANCER REGION; GENE; GENE EXPRESSION REGULATION; GENE MUTATION; GENE THERAPY; HEART; HOMEOBOX; HUMAN; HUMAN CELL; IMMEDIATE EARLY GENE; IN VITRO STUDY; IN VIVO STUDY; INVERTED CCAAT BOX; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY;

ANIMALS; ANTIGENS, NEOPLASM; APOPTOSIS REGULATORY PROTEINS; BREAST NEOPLASMS; CELL LINE, TUMOR; CYTOMEGALOVIRUS; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; ENHANCER ELEMENTS (GENETICS); FEMALE; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HUMANS; LIPOSOMES; MEMBRANE PROTEINS; MICE; MICE, NUDE; MUTATION; NEOPLASMS, EXPERIMENTAL; RESPONSE ELEMENTS;

ANIMALIA; CYTOMEGALOVIRUS;

EID: 33747592574     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700945     Document Type: Article

References (53)

1. Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL, Winngo PA et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003; 95: 1276-1299.
2. Rouse J, Jackson SP. Interfaces between the detection, signaling, and repair of DNA damage. Science 2002; 297: 547-551.
3. Kolodner RD, Putnam CD, Myung K. Maintenance of genome stability in Saccharomyces cerevisiae. Science 2002; 297: 552-557.
4. Maser RS, DePinho RA. Connecting chromosomes, crisis, and cancer. Science 2002; 297: 565-569.
5. Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB et al. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol 2001; 19: 3422-3433.
6. Ueno NT, Bartholomeusz C, Xia W, Anklesaria P, Bruckheimer EM, Mebel E et al. Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene. Cancer Res 2002; 62: 6712-6716.
7. Yoo GH, Hung MC, Lopez-Berestein G, LaFollete S, Ensley JF, Carey M et al. Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin Cancer Res 2001; 7: 1237-1245.
8. Dummer R, Bergh J, Karlsson Y, Horowitz JA, Mulder NH, Huinink DTB et al. Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors. Cancer Gene Ther 2000; 7: 1069-1076.
9. Pandha HS, Martin LA, Rigg A, Hurst HC, Stamp GW, Sikora K et al. Genetic prodrug activation therapy for breast cancer: a phase I clinical trial of erbB-2-directed suicide gene expression. J Clin Oncol 1999; 17: 2180-2189.
10. Saukkonen K, Hemminki A. Tissue-specific promoters for cancer gene therapy. Expert Opin Biol Ther 2004; 4: 683-696.
11. Brand K, Loser P, Arnold W, Bartels T, Strauss M. Tumor cell-specific transgene expression prevents liver toxicity of the adeno-HSVtk/GCV approach. Gene Therapy 1998; 5: 1363-1371.
12. Ikegami S, Tadakuma T, Ono T, Suzuki S, Yoshimura I, Asano T et al. Treatment efficiency of a suicide gene therapy using prostate-specific membrane antigen promoter/enhancer in a castrated mouse model of prostate cancer. Cancer Sci 2004; 95: 367-370.
13. Haviv YS, Curiel DT. Conditional gene targeting for cancer gene therapy. Adv Drug Deliv Rev 2001; 53: 135-154.
14. Lu H, Zhang Y, Roberts DD, Osborne CK, Templeton NS. Enhanced gene expression in breast cancer cells in vitro and tumors in vivo. Mol Ther 2002; 6: 783-792.
15. Templeton NS, Lasic DD, Frederik PM, Strey HH, Roberts DD, Pavlakis GN. Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol 1997; 15: 647-652.
16. Barron LG, Szoka Jr FC. The perplexing delivery mechanism of lipoplexes. In: Huang L, Hung MC, Wagner E (eds). Non-viral Vectors for Gene Therapy. Academic Press: San Diego, CA, 1999, pp 229-266.
17. Li S, Rizzo MA, Bhattacharya S, Huang L. Characterization of cationic lipid-protamine-DNA (LPD) complexes for intravenous gene delivery. Gene Therapy 1998; 5: 930-937.
18. Zou Y, Peng H, Zhou B, Wen Y, Wang SC, Tsai EM et al. Systemic tumor suppression by the proapoptotic gene bik. Cancer Res 2002; 62: 8-12.
19. Anderson LM, Krotz S, Weitzman SA, Thimmapaya B. Breast cancer-specific expression of the Candida albicans cytosine deaminase gene using a transcriptional targeting approach. Cancer Gene Ther 2000; 7: 845-852.
20. Katabi MM, Chan HL, Karp SE, Batist G. Hexokinase type II: a novel tumor-specific promoter for gene-targeted therapy differentially expressed and regulated in human cancer cells. Hum Gene Ther 1999; 10: 155-164.
21. Lin T, Huang X, Gu J, Zhang L, Roth JA, Xiong M et al. Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. Oncogene 2002; 21: 8020-8028.
22. Hung MC, Hortobagyi GN, Ueno NT. Development of clinical trial of E1A gene therapy targeting HER-2/neuoverexpressing breast and ovarian cancer. Adv Exp Med Biol 2000; 465: 171-180.
23. Adachi N, Nomoto M, Kohno K, Koyama H. Cell-cycle regulation of the DNA topoisomerase IIalpha promoter is mediated by proximal CCAAT boxes: possible involvement of acetylation. Gene 2000; 245: 49-57.
24. Falck J, Jensen PB, Sehested M. Evidence for repressional role of an inverted CCAAT box in cell cycle-dependent transcription of the human DNA topoisomerase IIalpha gene. J Biol Chem 1999; 274: 18753-18758.
25. Hochhauser D, Stanway CA, Harris AL, Hickson ID. Cloning and characterization of the 50-flanking region of the human topoisomerase II alpha gene. J Biol Chem 1992; 267: 18961-18965.
26. Li YM, Wen Y, Zhou BP, Kuo HP, Ding Q, Hung MC. Enhancement of Bik antitumor effect by Bik mutants. Cancer Res 2003; 63: 7630-7633.
27. Kurachi S, Hitomi Y, Furukawa M, Kurachi K. Role of intron I in expression of the human factor IX gene. J Biol Chem 1995; 270: 5276-5281.
28. Xu X, Lotan R. Nonisotopic in situ hybridization for the detection of nuclear retinoid receptor transcripts in tissue sections. Methods Mol Biol 1998; 89: 233-246.
29. Sitzmann J, Noben-Trauth K, Kamano H, Klempnauer KH. Expression of B-Mybduring mouse embryogenesis. Oncogene 1996; 12: 1889-1894.
30. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003; 100: 10393-10398.
31. van 't Veer LJ, Dai H, van de Vijver MJ, He JD, Hart AA, Bernards R et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536.
32. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
33. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009.
34. Nacht M, Ferguson AT, Zhang W, Petroziello JM, Cook BP, Gao YH et al. Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer. Cancer Res 1999; 59: 5464-5470.
35. Leerkes MR, Caballero OL, Mackay A, Torloni H, O'Hare MJ, Simpson AJ et al. In silico comparison of the transcriptome derived from purified normal breast cells and breast tumor cell lines reveals candidate upregulated genes in breast tumor cells. Genomics 2002; 79: 257-265.
36. Castagnetta LA, Agostara B, Montalto G, Polito L, Campisi I, Saetta A et al. Local estrogen formation by nontumoral, cirrhotic, and malignant human liver tissues and cells. Cancer Res 2003; 63: 5041-5045.
37. Woessner RD, Mattern MR, Mirabelli CK, Johnson RK, Drake FH. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ 1991; 2: 209-214.
38. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 2003; 36: 131-149.
39. van den Heuvel S, Harlow E. Distinct roles for cyclin-dependent kinases in cell cycle control. Science 1993; 262: 2050-2054.
40. Xu L, Daly T, Gao C, Flotte TR, Song S, Byrne BJ et al. CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice. Hum Gene Ther 2001; 12: 563-573.
41. Yi Y, Hahm SH, Lee KH. Retroviral gene therapy: safety issues and possible solutions. Curr Gene Ther 2005; 5: 25-35.
42. Marshall E. Gene therapy. Viral vectors still pack surprises. Science 2001; 294: 1640.
43. Yun J, Chae HD, Choi TS, Kim EH, Bang YJ, Chung J et al. Cdk2-dependent phosphorylation of the NF-Y transcription factor and its involvement in the p53-p21 signaling pathway. J Biol Chem 2003; 278: 36966-36972.
44. Joshi AA, Wu Z, Reed RF, Suttle DP. Nuclear factor-Y binding to the topoisomerase IIalpha promoter is inhibited by both the p53 tumor suppressor and anticancer drugs. Mol Pharmacol 2003; 63: 359-367.
45. Mendoza N, Fong S, Marsters J, Koeppen H, Schwall R, Wickramasinghe D. Selective cyclin-dependent kinase 2/cyclin A antagonists that differ from ATP site inhibitors block tumor growth. Cancer Res 2003; 63: 1020-1024.
46. Chen YN, Sharma SK, Ramsey TM, Jiang L, Martin MS, Baker K et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci USA 1999; 96: 4325-4329.
47. Baillie CT, Winslet MC, Bradley NJ. Tumour vasculature - a potential therapeutic target. Br J Cancer 1995; 72: 257-267.
48. Kan Z, Ivancev K, Lunderquist A, McCuskey PA, McCuskey RS, Wallace S. In vivo microscopy of hepatic tumors in animal models: a dynamic investigation of blood supply to hepatic metastases. Radiology 1993; 187: 621-626.
49. Liotta LA, Saidel MG, Kleinerman J. The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res 1976; 36: 889-894.
50. Thurston G, McLean JW, Rizen M, Baluk P, Haskell A, Murphy TJ et al. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Invest 1998; 101: 1401-1413.
51. McLean JW, Thurston G, McDonald DM. Sites of uptake and expression of cationic liposome/DNA complexes injected intravenously. In: Huang L, Hung M-C, Wagner E (eds). Nonviral Vectors for Gene Therapy. Academic Press: San Diego, CA, 1999, pp 120-134.
52. Boyd JM, Gallo GJ, Elangovan B, Houghton AB, Malstrom S, Avery BJ et al. Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins. Oncogene 1995; 11: 1921-1928.
53. Han J, Sabbatini P, White E. Induction of apoptosis by human Nbk/Bik, a BH3-containing protein that interacts with E1B 19K. Mol Cell Biol 1996; 16: 5857-5864.